EUVIMEDSkopri EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

Randomised clinical trial: Efficacy and safety of on‐demand vonoprazan versus placebo for non‐erosive reflux disease

Ronnie Fass iD, Michael Vaezi, Prateek Sharma iD, Rena Yadlapati, Barbara Hunt, Tom Harris, Neila Smith, Eckhard Leifke, David Armstrong iD

Alimentary Pharmacology & Therapeutics · 2023-11 · 58 (10) · 1016-1027

DOI: 10.1111/apt.17728 ↗

At a glance

Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, published online on 2023-09-26. Written by Ronnie Fass and 8 co-authors. Institution: The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical System, Case Western Reserve University, Cleve…. Major MEDLINE topics: Heartburn, Gastroesophageal Reflux. Cited 46 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Non‐erosive reflux disease (NERD) symptoms are often episodic, making on‐demand treatment an attractive treatment approach.

Aims

We compared the efficacy and safety of on‐demand vonoprazan versus placebo in patients with NERD.

Methods

Patients with NERD, defined as heartburn for ≥6 months and for ≥4/7 consecutive days with normal endoscopy, received once‐daily vonoprazan 20 mg during a 4‐week run‐in period. Patients without heartburn during the last 7 days and with ≥80% study drug and diary compliance were randomised 1:1:1:1 to vonoprazan 10, 20, 40 mg or placebo on‐demand for 6 weeks. The primary endpoint was the percentage of evaluable heartburn episodes completely relieved within 3 h of on‐demand dosing and sustained for 24 h.

Results

Of 458 patients in the run‐in period, 207 entered the on‐demand period. In the vonoprazan 10 mg group, 56.0% (201/359) of evaluable heartburn episodes met the criteria for complete and sustained relief; 60.6% (198/327) in the 20 mg group; and 70.0% (226/323) in the 40 mg group, compared with 27.3% (101/370) in the placebo group ( p < 0.0001 versus placebo for each vonoprazan group). By 1 h post‐dose, vonoprazan was associated with complete relief of significantly more heartburn episodes compared with placebo. No serious treatment‐emergent adverse events were reported.

Conclusion

On‐demand vonoprazan may be a potential alternative to continued daily acid suppression therapy for the relief of episodic heartburn in patients with NERD. Clinicaltrials.gov : NCT04799158.

Subjects

MeSH terms (MEDLINE)

HeartburnGastroesophageal RefluxHumansPyrrolesSulfonamidesTreatment OutcomeProton Pump Inhibitors

Author keywords

GERDacidity (intragastric)acidity (oesophageal)

Substances

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrrolesSulfonamidesProton Pump Inhibitors

Authors and institutions

  • The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical System, Case Western Reserve University, Cleveland, Ohio, USA.
  • Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Gastroenterology and Hepatology, Kansas City VA Medical Center, Kansas City, Missouri, USA.
  • Department of Gastroenterology and Hepatology, University of Kansas School of Medicine, Kansas City, Kansas, USA.
  • Division of Gastroenterology, Center for Esophageal Diseases, University of California, San Diego, California, USA.
  • Phathom Pharmaceuticals, Research and Development, Buffalo Grove, Illinois, USA.

ORCID profiles: Ronnie Fass, Prateek Sharma, David Armstrong

Cite

APA

Fass, R., Vaezi, M., Sharma, P., Yadlapati, R., Hunt, B., Harris, T., Smith, N., Leifke, E., & Armstrong, D. (2023). Randomised clinical trial: Efficacy and safety of on‐demand vonoprazan versus placebo for non‐erosive reflux disease. Alimentary Pharmacology & Therapeutics, 58(10), 1016-1027. https://doi.org/10.1111/apt.17728

Vancouver

Fass R, Vaezi M, Sharma P, Yadlapati R, Hunt B, Harris T, et al. Randomised clinical trial: Efficacy and safety of on‐demand vonoprazan versus placebo for non‐erosive reflux disease. Alimentary Pharmacology & Therapeutics. 2023;58(10):1016-1027. doi:10.1111/apt.17728

BibTeX
@article{Fass2023,
  author = {Fass, Ronnie and Vaezi, Michael and Sharma, Prateek and Yadlapati, Rena and Hunt, Barbara and Harris, Tom and Smith, Neila and Leifke, Eckhard and Armstrong, David},
  title = {Randomised clinical trial: Efficacy and safety of on‐demand vonoprazan versus placebo for non‐erosive reflux disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {58},
  number = {10},
  pages = {1016--1027},
  doi = {10.1111/apt.17728}
}
Start for free →